A Multi-Center, Double-Bind, Placebo-Controlled Phase IIa Study to Evaluate an Investigational Medicine to Treat Mild-Stage Alzheimer's Disease (CONNECT)

The CONNECT study will test whether an oral, experimental drug, AZD0530 (Saracatinib), will slow progression in mild-stage Alzheimer's disease (AD). Although the cause of AD is unknown, several lines of evidence suggest that a peptide known as beta-amyloid plays a central role.  Convergent evidence in recent years has yielded a refinement of the "amyloid hypothesis", suggesting that neurotoxicity of beta-amyloid oligomers leads to Alzheimer's disease.

Researchers are looking for people who:

-- are 55-85 years of age,

-- have a diagnosis of mild Alzheimer's disease,

-- are willing to undergo a variety of clinic assessments,

-- have a study partner willing to attend clinic visits and have at least 10 hours/week of contact with study participant.

A study flyer with more details is attached.